Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity.

ABSTRACT:

Background

In mid-December 2020, Israel started a nationwide mass vaccination campaign against coronavirus disease 2019 (COVID-19). In the first few weeks, medical personnel, elderly citizens, and patients with chronic diseases were prioritized. As such, patients with primary and secondary immunodeficiencies were encouraged to receive the vaccine. Although the efficacy of RNA-based COVID-19 vaccines has been demonstrated in the general population, little is known about their efficacy and safety in patients with inborn errors of immunity (IEI).

Objective

Our aim was to evaluate the humoral and cellular immune response to COVID-19 vaccine in a cohort of patients with IEI.

Methods

A total of 26 adult patients were enrolled, and plasma and peripheral blood mononuclear cel

SUBMITTER: Hagin D 

PROVIDER: S-EPMC8168345 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature